Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

JRNY vs. SBIO: which is better?

Bottom line

JRNY vs SBIO: the short answer

JRNY (ALPS Global Travel Beneficiaries ETF) and SBIO (ALPS Medical Breakthroughs ETF) are both etfs.

Updated Nov 19, 2026

JRNY vs SBIO side by side

JRNYSBIO
TypeETFETF
Fund familyAlpsAlps
CategoryGlobal StockHealth Care Sector
Expense ratio—0.5%
Annual cost per $10k—$50
10-yr cost on $10k (prospectus)—$628
Max front loadNoneNone
12b-1 fee——
1-yr return—+54.2%
5-yr return (annualized)—+0.7%
10-yr return (annualized)—+5.7%
Best quarter—+33.9%
Worst quarter—−30.8%
Net assets (fund)—$161.8M
Number of holdings—89
Portfolio turnover—58%
Returns as of—Dec 31, 2025

Source: SEC Form N-PORT and fund prospectuses

Holdings overlap

JRNY and SBIO share none of their top holdings.

JRNY top 10

    SBIO top 10

    1. Alkermes Plc — 4.48%
    2. Kymera Therapeutics Inc — 4.23%
    3. Celcuity Inc — 3.92%
    4. Mirum Pharmaceuticals Inc — 3.90%
    5. Spyre Therapeutics Inc — 3.68%
    6. Cg Oncology Inc — 3.35%
    7. Apogee Therapeutics Inc — 2.93%
    8. Xenon Pharmaceuticals Inc — 2.90%
    9. Travere Therapeutics Inc — 2.77%
    10. Dianthus Therapeutics Inc — 2.64%

    FAQ

    What is the difference between JRNY and SBIO?
    JRNY (ALPS Global Travel Beneficiaries ETF) and SBIO (ALPS Medical Breakthroughs ETF) are both etfs.
    Should I own both JRNY and SBIO?
    Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.

    Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.